Risk factors for falls with use of acid-suppressive drugs

Epidemiology

Volumn 24, Issue 4, 2013, Pages 600-607

  Cea Soriano, Lucía ^a   Johansson, Saga ^b   García Rodríguez, Luis A ^a  

^a CEIFE ^*  (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; STEROID; VITAMIN D;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FALL RISK; FALLING; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; UNITED KINGDOM;

ACCIDENTAL FALLS; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FRACTURES, BONE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84879884280     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e318294bec6     Document Type: Article

References (34)

1. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139: 1115-1127.
2. C orley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139: 93-101.
3. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20: 1989-1998.
4. E om CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9: 257-267.
5. N gamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta- analysis of observational studies. Am J Gastroenterol. 2011;106:1209- 1218; quiz 1219.
6. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2011;22: 903-910.
7. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79: 76-83.
8. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296: 2947-2953.
9. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124: 519-526.
10. T inetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319: 1701-1707.
11. Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in older people in the United Kingdom. J Epidemiol Community Health. 2003;57: 740-744.
12. G raafmans WC, Ooms ME, Hofstee HM, Bezemer PD, Bouter LM, Lips P. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol. 1996;143: 1129-1136.
13. O'Neil M, Payne C, Read J. Read Codes Version 3: a user led terminology. Methods Inf Med. 1995;34: 187-192.
14. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp. 1996: 75-79.
15. First Databank. MULTILE X for primary care; 2010. Available at: http:// www.fdbhealth.co.uk/multilex-overview/. Accessed 4 December 2012.
16. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Informatics in Primary Care. 2011;19: 251-255.
17. L ewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16: 393-401.
18. G ribbin J, Hubbard R, Smith C, Gladman J, Lewis S. Incidence and mortality of falls amongst older people in primary care in the United Kingdom. QJM. 2009;102: 477-483.
19. R odríguez LA, Ruigómez A, Wallander MA, Johansson S. Acidsuppressive drugs and community-acquired pneumonia. Epidemiology. 2009;20: 800-806.
20. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf. 2009;18: 697-703.
21. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2009;18: 269-275.
22. L ustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2012;30: 3665-3674.
23. G uise TA . Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11: 1121-1131.
24. Walker AM. Case-control studies:sampling the source population. In: Walker AM, ed. Observation and Inference: An Introduction to the Methods of Epidemiology. Chestnut Hill, MA: Epidemiology Resources Inc.; 1991: 75-80.
25. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993;22: 1189-1192.
26. I smail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 2002;13: 565-571.
27. Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology. 2010;21: 658-668.
28. Bloch F, Thibaud M, Dugué B, Brèque C, Rigaud AS, Kemoun G. Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health. 2011;23: 329-346.
29. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging. 2009;26: 381-394.
30. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62: 1172-1181.
31. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169: 1952-1960.
32. T odd C, Skelton D. What Are the Main Risk Factors for Falls Among Older People and What Are the Most Effective Interventions to Prevent These Falls? Health Evidence Network Report. Copenhagen, Denmark: WHO Regional Office for Europe; 2004.
33. G ribbin J, Hubbard R, Gladman JR, Smith C, Lewis S. Risk of falls associated with antihypertensive medication: population-based case-control study. Age Ageing. 2010;39: 592-597.
34. C ummings SR, Nevitt MC, Kidd S. Forgetting falls. The limited accuracy of recall of falls in the elderly. J Am Geriatr Soc. 1988;36: 613-616.